COMMUNIQUÉS West-GlobeNewswire

Lungpacer Medical Announces First Enrollments in STARI Trial of Next-Generation Neurostimulation Therapy
04/11/2025
STARI will investigate continual diaphragm neurostimulation to improve lung, diaphragm, cardiac and brain function at the earliest stages of mechanical ventilation EXTON, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lungpacer [...]
Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control
04/11/2025
-- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control -- -- Phase 2 program for AMT-143 expected to begin in 2026 -- BRISBANE, [...]
Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
04/11/2025
Initial results of a Phase 1 / 2 open label study of AT-02, the company’s lead pan-amyloid removal therapeutic candidate, in patients with AL amyloidosis will be presented at ASH. The presentation includes data on AL [...]
Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R
04/11/2025
SOL-R, the second registrational trial of AXPAXLI™ in wet AMD, remains on track for topline data in 1H 2027 Together with SOL-1, these complementary trials are expected to form the basis of a potential NDA submission [...]
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
04/11/2025
MELBOURNE, Australia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent [...]
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
04/11/2025
Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026 Novel immunomodulatory regimen designed to reduce calcineurin [...]
Secura Bio Announces Poster Presentation Highlighting Extended Follow Up Analyses from Phase 2 PRIMO Trial at the 2025 American Society of Hematology Meeting
04/11/2025
BERKELEY HEIGHTS, N. J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced a poster [...]
Purespring to present three posters at the American Society of Nephrology Kidney Week 2025
04/11/2025
New information to be presented on the study design and methodology of Purespring’s Phase I/II trial of PS-002, an AAV-based therapy delivering the complement factor I to podocytes in patients with IgA nephropathy [...]
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
04/11/2025
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs [...]
EDAP to Present at Jefferies Global Healthcare Conference in London
04/11/2025
EDAP to Present at Jefferies Global Healthcare Conference in London Company to Present and Host 1x1 Investor Meetings on Tuesday, November 18 th , 2025 AUSTIN, Texas, November 4, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the [...]
InspireMD Reports Third Quarter 2025 Financial Results
04/11/2025
Successful initial CGuard Prime U.S. commercial launch drives record quarterly revenue MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® [...]
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer
04/11/2025
Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized [...]
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
04/11/2025
Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with [...]
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
04/11/2025
Platinum sponsorship of NF Caregivers Symposium reinforces commitment to NF1 community MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage [...]
Zelluna ASA: Notice of extraordinary general meeting on 25 November 2025
04/11/2025
Oslo, 4 November 2025: Reference is made to the stock exchange notice published by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement and retail offering. The Company's board of [...]
Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights
04/11/2025
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved target randomization [...]
Prelude Therapeutics Announces Strategic Business Update
04/11/2025
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement [...]
Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan
04/11/2025
Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro [...]
Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
04/11/2025
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the [...]

Pages